EtO Sterilization

● CAMPAIGN OPEN ACTIVE TRIALS / SETTLEMENT 1 signals
Cancer (breast, non-Hodgkin lymphoma)  ·  Ethylene Oxide (EtO) Sterilization Emissions
DEFENDANT
Sterigenics / Medline / BD
MDL / DOCKET
N.D. Illinois (coordinated)
N.D. Illinois
JUDGE
Various
PLAINTIFFS
600+
BELLWETHER / TRIAL
Ongoing trials
SETTLEMENT STATUS
Sterigenics $408M (Willowbrook IL)
📋 Case Overview

Ethylene oxide (EtO) is used to sterilize medical devices and is classified by EPA and IARC as a Group 1 human carcinogen. Industrial sterilization facilities emit EtO, exposing nearby communities. Sterigenics settled $408M for Willowbrook, IL community. Cases continue against Medline Industries (Waukegan, IL), BD (Covington, GA), and other facility operators.

⚗ CAUSATION SUMMARY

EtO is an alkylating agent that directly damages DNA. IARC Group 1 classification (definite human carcinogen). Breast cancer and non-Hodgkin lymphoma are the primary injury categories supported by occupational cohort and community exposure studies. Residential proximity analysis is the key causation link.

⚖️ Litigation Status GROWING
MDL / Court
N.D. Illinois — Consolidation (Not formal MDL)
Active Plaintiffs
2,000+

Ethylene oxide sterilization facility cases are pending in N.D. Illinois (Sterigenics/Willowbrook) and other jurisdictions. EtO is a known carcinogen. EPA has taken aggressive action. Cases involve workers and community members exposed near sterilization facilities.

Key Verdicts & Settlements
⚖️
Sterigenics Willowbrook trial — $363M verdict (2022)
First major EtO verdict. Plaintiff Susan Kamuda awarded $363M in Illinois state court. Established massive liability.
💰
Sterigenics settlement fund — $408M (2023)
Global settlement following the Kamuda verdict. Set per-case benchmarks for future claims.
📈
Filing trend: Growing. Sterigenics verdict and settlement established strong precedent. Other EtO facilities (Becton Dickinson, others) are next targets. Community exposure claims are viable.
📍 Geographic Exposure
●Willowbrook, IL (Sterigenics, resolved $408M)
●Waukegan, IL (Medline Industries — active)
●Covington, GA (Becton Dickinson — active)
●Laredo, TX (STERIS)
●Atlanta, GA (Becton Dickinson facilities)
🏢 Key Defendants
DEFENDANT
ROLE
INTEL NOTE
Sterigenics International
Primary facility operator
$408M Willowbrook IL settlement; other facilities still operating
Medline Industries
Facility operator (Waukegan IL)
Active litigation; large residential exposure area
Becton Dickinson (BD)
Facility operator (Covington GA)
Active litigation in Georgia
STERIS
Facility operator (Laredo TX)
Emerging litigation
✅ Campaign Eligibility Criteria
✓Lived or worked within 1-3 miles of identified EtO sterilization facility for 1+ years
✓Diagnosed with breast cancer, non-Hodgkin lymphoma, or other EtO-linked cancers
✓Residential proximity analysis required — plaintiff must be in documented exposure zone
✓Within 2 years of diagnosis date
These criteria reflect general case strength indicators and are not legal advice. Contact CloudIntake to screen individual claimants.
📅 Litigation Timeline
2016
EPA updates EtO risk assessment; dramatically increases risk estimate
2018
EPA's NATA report identifies Willowbrook IL and Smyrna GA as highest-risk census tracts in U.S.
2018
First Sterigenics lawsuits filed in Illinois; facility temporarily closed
2022
Sterigenics settles 870 Willowbrook cases for $408M
2023
EPA proposes strict EtO emission rules; accelerates new litigation
2024
Medline and BD cases proceed; new facilities identified
EtO Sterilization — Intelligence Feed LIVE
📰 NEWS
Ga. Panel Says McClain Standard Applies In Sterigenics Case
Mar 13, 2026 Law360 Read Source →
Feed All Torts
MASS TORT AD AGENCY
First-mover advantage is real.
Early-stage MDLs have the lowest CPLs. Once bellwether trials start, costs triple. MTAA is running EtO Sterilization campaigns now.
Lock In Your Rates →
Plaintiff attorneys only · mtaa.ai
JACOB SCORE™
EtO Sterilization
54 / 100
ScienceModerate
MomentumDeveloping
CampaignModerate
TimelineDeveloping
VerdictsDeveloping
INDUSTRIAL EXPOSURE · DEVELOPING
Jacob Score™ — Methodology & Legal Disclaimers
The Jacob Score is a composite 1–100 litigation opportunity index for mass torts, produced by the TortIntel editorial team at Mass Tort Ad Agency. It is updated periodically as litigation conditions change.

Score Dimensions (each rated 1–5)

Science — Peer-reviewed study quality and quantity, relative risk magnitude, replication across independent research groups, FDA or regulatory action taken, and estimated Daubert survivability based on published expert testimony and prior rulings.

Momentum — MDL formation and phase, plaintiff count trajectory, case consolidation activity, and overall litigation velocity.

Campaign — Current filing window status, case saturation, defendant solvency, estimated qualifying population size, and co-defendant dynamics.

Timeline — Proximity to first expected resolution or bellwether trial, current discovery or Daubert phase, and estimated time-to-value for a signed plaintiff.

Verdicts — Confirmed plaintiff jury verdicts, bellwether trial win/loss record, and size or certainty of any established settlement fund. 1 = pre-trial · 2 = mixed early results · 3 = partial settlements or initial wins · 4 = confirmed large verdicts or funded settlement · 5 = landmark verdicts with formal settlement program.

LEGAL DISCLAIMERS

The Jacob Score and all associated content on TortIntel.ai is provided solely for mass tort business intelligence and law firm marketing decision-making purposes. It does not constitute legal advice, litigation strategy advice, or a recommendation to file or refrain from filing any lawsuit.

The Jacob Score is an editorial opinion based on publicly available data including court filings, published scientific literature, regulatory actions, and reported settlement information. It is not a guarantee of future litigation outcomes. Past verdicts and settlements are not predictive of future results in any specific case.

TortIntel.ai and Mass Tort Ad Agency make no representation that any score is complete, accurate, or current. Litigation conditions change rapidly. Attorneys must conduct independent due diligence and consult qualified co-counsel before making any case acquisition or litigation funding decisions based on this or any other intelligence tool.

This score must not be used to evaluate, accept, or reject any individual plaintiff’s case. Case-specific merit depends on individual facts, applicable state law, expert medical and scientific analysis, and jurisdiction-specific statutes of limitations — all of which are beyond the scope of this tool.

No attorney-client relationship is created by use of this platform. TortIntel.ai is not a law firm and does not provide legal services. © 2026 Mass Tort Ad Agency / TortIntel.ai. All rights reserved.
DATA ACCURACY
See something incorrect? Reach out and we'll fix it.
🔔 Alert Me
Get notified when EtO Sterilization updates.
✓ You're subscribed. We'll notify you of key developments.
TORTINTEL PRO
Abuse Discovery Tracker
Emerging institutional abuse cases — church, scouting, youth programs. Real-time defendant monitoring, filing window alerts, and filing cluster detection.
View Pro Features →